- Home
- Automated
- NDF A-Z listing
- Dinutuximab Beta
D
Dinutuximab Beta
Subsidy Information and Financing Scheme
MSHL
Drug Guidance
No
Post-marketing information
No
Summary of Biologics
No
Active ingredient: Dinutuximab Beta
General information
Subsidy Information and Financing Scheme
[MSHL] Dinutuximab beta Concentrate For Solution For Infusion 20 mg/4.5 mL
Treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.
Treatment of patients with history of relapsed or refractory neuroblastoma, with or without residual disease.
Legend
This section shows the following:
Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs
Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List
Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List
As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.
Legend list
Indicator | Legend |
|---|---|
SDL | Standard Drug List |
MAF | Medical Assistance Fund |
SVL | Subsidised Vaccine List |
MSHL | Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List |
Drug Guidance for Subsidy
Not Applicable